Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
21 Jul 23
10-Q
2023 Q1
Quarterly report
17 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K/A
2022 FY
Annual report (amended)
10 Apr 23
10-K
2022 FY
Annual report
21 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
8-K
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 24
8-K
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Feb 24
8-K
AEON Biopharma Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
19 Oct 23
8-K
Changes in Registrant's Certifying Accountant
2 Oct 23
Registration and prospectus
S-1/A
IPO registration (amended)
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
S-1/A
IPO registration (amended)
22 Nov 23
S-1/A
IPO registration (amended)
20 Oct 23
S-1
IPO registration
18 Aug 23
25
Voluntary exchange delisting
21 Jul 23
8-A12B
Registration of securities on exchange
21 Jul 23
S-4MEF
Addition of securities to prior registration
18 Jul 23
425
Business combination disclosure
17 Jul 23
425
Business combination disclosure
11 Jul 23
Proxies
PRE 14A
Preliminary proxy
17 Apr 24
DEFA14A
Additional proxy soliciting materials
30 Jun 23
DEFA14A
Additional proxy soliciting materials
29 Jun 23
DEFA14A
Additional proxy soliciting materials
28 Jun 23
DEFA14A
Additional proxy soliciting materials
26 Jun 23
DEFA14A
Additional proxy soliciting materials
21 Jun 23
DEFA14A
Additional proxy soliciting materials
15 Jun 23
DEFA14A
Additional proxy soliciting materials
13 Jun 23
DEFA14A
Additional proxy soliciting materials
8 Jun 23
DEFA14A
Additional proxy soliciting materials
5 Jun 23
Other
CERT
Certification of approval for exchange listing
21 Jul 23
EFFECT
Notice of effectiveness
12 May 23
CORRESP
Correspondence with SEC
11 May 23
CORRESP
Correspondence with SEC
9 May 23
UPLOAD
Letter from SEC
8 May 23
CORRESP
Correspondence with SEC
1 May 23
UPLOAD
Letter from SEC
23 Mar 23
CORRESP
Correspondence with SEC
9 Mar 23
UPLOAD
Letter from SEC
27 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
Ownership
3
Seongsoo Park
18 Apr 24
4/A
Change in insider ownership (amended)
16 Apr 24
4
Change in insider ownership
12 Apr 24
4
Change in insider ownership
26 Mar 24
4
Shelley B Thunen
21 Mar 24
4
ROBERT J PALMISANO
21 Mar 24
4
Marc Forth
21 Mar 24
4
Chad Oh
21 Mar 24
4
JOST FISCHER
21 Mar 24
4
Eric G Carter
21 Mar 24